This is a table of type proper and their frequencies. Use it to search & browse the list to learn more about your study carrel.
proper | frequency |
---|---|
CMV | 4633 |
HSCT | 4309 |
T | 3055 |
der | 2778 |
GVHD | 2391 |
mg | 1696 |
HLA | 1536 |
von | 1471 |
SCT | 1431 |
CD4 | 1347 |
HIV | 1280 |
mit | 1260 |
PCR | 1159 |
bei | 1140 |
OS | 1125 |
EBV | 1061 |
AML | 1030 |
eine | 1029 |
B | 1010 |
und | 971 |
CD8 | 949 |
werden | 932 |
GvHD | 896 |
CD34 | 880 |
ATG | 845 |
C | 825 |
NK | 814 |
CI | 768 |
zu | 759 |
II | 751 |
einer | 747 |
kg | 746 |
IV | 710 |
ASCT | 703 |
sind | 686 |
HCT | 670 |
oder | 662 |
G | 654 |
IFN | 599 |
durch | 588 |
University | 576 |
RIC | 573 |
CR | 562 |
A | 542 |
ist | 531 |
den | 530 |
auf | 530 |
aGVHD | 530 |
DC | 522 |
el | 502 |
± | 501 |
RNA | 498 |
nach | 492 |
nicht | 486 |
BM | 485 |
Patienten | 483 |
NRM | 476 |
CSF | 473 |
CD3 | 467 |
Infektion | 463 |
sich | 461 |
DNA | 461 |
MRD | 458 |
Hospital | 455 |
TCR | 444 |
das | 437 |
Therapie | 434 |
auch | 422 |
zur | 421 |
HCV | 417 |
B. | 411 |
DLI | 411 |
kann | 407 |
wird | 399 |
¼ | 391 |
MM | 391 |
HSV | 390 |
C. | 388 |
Infektionen | 387 |
Bei | 386 |
PFS | 385 |
Background | 384 |
S. | 383 |
TRM | 378 |
TBI | 378 |
ECP | 377 |
Table | 374 |
III | 372 |
M. | 372 |
MDS | 370 |
HR | 356 |
SCID | 352 |
IgG | 352 |
es | 348 |
VOD | 346 |
ELISA | 339 |
Treg | 339 |
des | 337 |
• | 320 |
EBMT | 320 |
RSV | 319 |
M | 318 |
L | 318 |
IgM | 317 |
BK | 316 |
Group | 315 |
PBSC | 315 |
van | 313 |
MHC | 308 |
AIDS | 307 |
range | 303 |
Fig | 302 |
cGVHD | 299 |
A. | 296 |
als | 292 |
I | 291 |
Cy | 288 |
TNF | 287 |
BMT | 286 |
ein | 285 |
HBV | 282 |
IVIG | 280 |
DeepRC | 280 |
ICU | 279 |
P. | 277 |
los | 272 |
PTLD | 270 |
CT | 266 |
dem | 262 |
Candida | 259 |
Cytomegalovirus | 256 |
F | 255 |
können | 253 |
vor | 252 |
VZV | 250 |
alloSCT | 248 |
NHL | 247 |
Eine | 246 |
CGD | 244 |
BKV | 244 |
IL-6 | 242 |
aus | 234 |
CD19 | 234 |
Transplantation | 232 |
þ | 231 |
E. | 231 |
January | 230 |
CVID | 230 |
un | 229 |
HHV-6 | 228 |
D | 228 |
S | 227 |
del | 224 |
GI | 224 |
Disease | 224 |
Hodgkin | 218 |
Center | 218 |
z. | 217 |
Pneumocystis | 217 |
PB | 216 |
United | 216 |
MSD | 215 |
Epstein | 215 |
CR1 | 215 |
LT | 214 |
Barr | 214 |
sowie | 211 |
MSC | 211 |
IgA | 210 |
allo | 203 |
Tregs | 203 |
Germany | 203 |
einem | 202 |
MMF | 202 |
DFS | 202 |
R | 201 |
haplo | 198 |
myeloablative | 198 |
PID | 196 |
WT | 195 |
TB | 194 |
bis | 192 |
Hepatitis | 190 |
MAC | 189 |
Es | 189 |
MS | 189 |
RT | 189 |
mycophenolate | 188 |
melphalan | 188 |
TMA | 188 |
Medical | 187 |
gegen | 186 |
IL-10 | 186 |
AA | 186 |
SOS | 183 |
Institute | 182 |
nur | 181 |
La | 179 |
Virus | 178 |
Der | 177 |
PT | 176 |
K | 176 |
States | 174 |
Nachweis | 174 |
Bu | 174 |
J. | 173 |
IL-2 | 173 |
HLH | 173 |
Department | 173 |
HL | 172 |
cytomegalovirus | 170 |
AUC | 170 |
pts | 170 |
een | 170 |
mofetil | 170 |
R. | 169 |
PR | 169 |
aber | 167 |
ganciclovir | 166 |
USA | 165 |
HC | 165 |
Das | 165 |
NKT | 164 |
CNS | 164 |
lymphopenia | 164 |
IU | 163 |
J | 160 |
HIV-1 | 160 |
L. | 159 |
dass | 158 |
G. | 155 |
National | 155 |
Herpes | 155 |
Erreger | 154 |
kommt | 152 |
India | 151 |
< | 151 |
trasplante | 150 |
meist | 150 |
het | 149 |
gd | 149 |
Research | 149 |
IL-4 | 149 |
Fieber | 149 |
BEAM | 149 |
Health | 148 |
CTL | 147 |
CML | 147 |
vivo | 147 |
en | 147 |
zum | 146 |
N | 146 |
alloHSCT | 145 |
Staphylococcus | 145 |
HSC | 145 |
Human | 144 |
December | 144 |
Medicine | 142 |
Hopfield | 142 |
über | 141 |
bzw | 141 |
una | 140 |
hepatitis | 140 |
Cell | 138 |
Immunology | 138 |
D. | 137 |
Tx | 136 |
ARDS | 135 |
wie | 134 |
CD25 | 134 |
methotrexate | 133 |
PCP | 133 |
Hematology | 133 |
SARS | 132 |
LSTM | 132 |
fl | 131 |
MUD | 131 |
Haplo | 131 |
SLE | 130 |
Erkrankung | 130 |
H. | 129 |
novo | 128 |
MRI | 128 |
Cox | 128 |
MTX | 128 |
TKI | 127 |
IBD | 127 |
CLL | 126 |
Allo | 126 |
Symptome | 126 |
für | 126 |
nd | 126 |
− | 126 |
i.v | 125 |
NIH | 125 |
LPS | 125 |
CD | 125 |
Infectious | 124 |
BALB | 124 |
CB | 124 |
häufig | 124 |
Patient | 124 |
Transplant | 124 |
tacrolimus | 124 |
T. | 123 |
KO | 122 |
E | 122 |
Adenovirus | 122 |
infección | 121 |
UCB | 121 |
TLR4 | 121 |
IL-17 | 121 |
Diseases | 120 |
ABO | 120 |
Antikörper | 120 |
BOS | 120 |
Stem | 120 |
Society | 120 |
TGF | 120 |
US | 119 |
sDC | 118 |
dl | 118 |
IgE | 118 |
F. | 118 |
EFS | 118 |
DSA | 117 |
mRNA | 117 |
CSA | 117 |
H | 116 |
ADA | 116 |
Fludarabine | 116 |
HTLV | 116 |
TA | 116 |
Zellen | 116 |
WBC | 115 |
AHSCT | 115 |
Kindern | 115 |
signifi | 115 |
West | 115 |
fi | 115 |
las | 115 |
sehr | 114 |
Tage | 114 |
Mycobacterium | 114 |
June | 114 |
× | 113 |
OLT | 113 |
CY | 113 |
CD56 | 113 |
Registry | 112 |
MIL | 112 |
November | 112 |
acyclovir | 112 |
Study | 112 |
keine | 112 |
Ig | 111 |
pacientes | 110 |
SOT | 110 |
Nach | 110 |
Behandlung | 110 |
De | 109 |
Busulfan | 109 |
N. | 109 |
jedoch | 109 |
tratamiento | 109 |
para | 108 |
HAART | 108 |
Impfung | 107 |
DCs | 107 |
Diagnostik | 107 |
GFR | 107 |
V | 107 |
LFS | 107 |
anti | 107 |
mL | 107 |
anderen | 106 |
U | 106 |
Marrow | 106 |
Erkrankungen | 106 |
CR2 | 106 |
por | 105 |
Viren | 105 |
SR | 105 |
SCD | 105 |
CNI | 104 |
ES | 104 |
Europe | 104 |
TLR | 104 |
posttransplant | 104 |
kommen | 103 |
einen | 103 |
NF | 103 |
KIR | 103 |
IL-18 | 103 |
sera | 102 |
Wochen | 102 |
Pts | 102 |
parainfluenza | 102 |
sie | 101 |
sein | 101 |
ml | 101 |
K. | 101 |
Clinical | 101 |
BAL | 99 |
International | 99 |
IFI | 99 |
worden | 98 |
Influenza | 98 |
ANC | 98 |
como | 97 |
cGvHD | 97 |
TCD | 97 |
October | 97 |
Kaplan | 97 |
Flu | 97 |
sollte | 96 |
GT | 96 |
CBT | 96 |
AR | 96 |
Children | 95 |
RI | 95 |
TREC | 95 |
alloHCT | 95 |
MNC | 94 |
July | 94 |
besteht | 93 |
Menschen | 93 |
Jahren | 93 |
con | 93 |
herpes | 93 |
unter | 93 |
Japan | 93 |
UCBT | 92 |
CNN | 92 |
AE | 92 |
UD | 91 |
Syndrome | 91 |
Pseudomonas | 91 |
C57BL/6 | 91 |
IA | 90 |
Unit | 90 |
Tab | 90 |
selten | 89 |
m2 | 89 |
allem | 89 |
SIGN | 89 |
SAA | 89 |
Rituximab | 89 |
RFS | 89 |
CsA | 89 |
BCR | 89 |
BCG | 89 |
α | 88 |
Meier | 88 |
APC | 88 |
IR | 87 |
Aspergillus | 87 |
March | 87 |
eines | 87 |
valganciclovir | 87 |
die | 86 |
MA | 86 |
CD28 | 86 |
C4d | 86 |
Komplikationen | 85 |
Die | 85 |
FACS | 85 |
IQR | 85 |
DLBCL | 85 |
Nile | 85 |
führen | 85 |
möglich | 85 |
sirolimus | 85 |
P | 85 |
PD | 84 |
Kinder | 84 |
st | 84 |
noch | 84 |
zwischen | 84 |
u. | 83 |
NL63 | 83 |
DMSO | 83 |
Cyclophosphamide | 83 |
Jahre | 82 |
CAR | 82 |
Anti | 82 |
-3 | 82 |
April | 81 |
GM | 81 |
IL-12 | 81 |
Allogeneic | 81 |
Ag | 81 |
HDT | 81 |
führt | 81 |
Italy | 81 |
mm | 81 |
tx | 81 |
Übertragung | 81 |
γ | 81 |
PNH | 81 |
gibt | 80 |
Y | 80 |
Gabe | 80 |
GRFS | 80 |
Disclosure | 80 |
CIK | 79 |
APRV | 79 |
A2 | 79 |
FDA | 79 |
UK | 79 |
MRSA | 79 |
beim | 78 |
URD | 78 |
Verlauf | 78 |
Cancer | 78 |
klinischen | 78 |
sha | 78 |
sulfamethoxazole | 78 |
treosulfan | 77 |
ruxolitinib | 77 |
September | 77 |
Committee | 77 |
CD14 | 77 |
Blut | 76 |
Ein | 76 |
Gy | 76 |
HCoV | 76 |
Hematopoietic | 76 |
schweren | 76 |
simplex | 76 |
IL-15 | 76 |
jirovecii | 75 |
SD | 75 |
May | 75 |
HPV | 75 |
Deutschland | 75 |
America | 75 |
Africa | 75 |
MMUD | 74 |
Blood | 74 |
I. | 74 |
Bone | 74 |
Pneumonie | 74 |
antithymocyte | 74 |
aplasia | 74 |
› | 74 |
AMR | 73 |
American | 73 |
Auftreten | 73 |
China | 73 |
Ganciclovir | 73 |
IRI | 73 |
Inkubationszeit | 73 |
Introduction | 73 |
MAbs | 73 |
MC | 73 |
ng | 73 |
Engraftment | 72 |
B19 | 72 |
DR | 72 |
Diese | 72 |
European | 72 |
PBMC | 72 |
RPTEC | 72 |
ohne | 72 |
post | 72 |
wenn | 72 |
engraftment | 71 |
defi | 71 |
Pediatric | 71 |
Oncology | 71 |
OM | 71 |
Fc | 71 |
H1N1 | 70 |
AL | 70 |
BMI | 70 |
FoxP3 | 70 |
Melphalan | 70 |
Interest | 70 |
MELD | 70 |
PET | 70 |
Prophylaxe | 69 |
BU | 69 |
CD40 | 69 |
CD45 | 69 |
CDC | 69 |
HD | 69 |
Als | 69 |
Tacrolimus | 69 |
mittels | 69 |
mucositis | 69 |
pDC | 69 |
specifi | 69 |
klinische | 69 |
HHV6 | 68 |
8) | 68 |
Cidofovir | 68 |
El | 68 |
Regel | 68 |
Kg | 68 |
alle | 68 |
maribavir | 68 |
Abstract | 67 |
BV | 67 |
ELISPOT | 67 |
RBC | 67 |
Risiko | 67 |
bij | 67 |
monocyte | 67 |
bekannt | 67 |
TNC | 66 |
CIR | 66 |
Gr | 66 |
Immune | 66 |
LC | 66 |
PTCY | 66 |
Treatment | 66 |
dieser | 66 |
klinisch | 66 |
más | 66 |
n=10 | 66 |
profilaxis | 66 |
IL-8 | 65 |
CRS | 65 |
HDCT | 65 |
Bakterien | 65 |
Immunodeficiency | 65 |
enfermedad | 65 |
RR | 65 |
wurde | 64 |
behandelt | 64 |
le | 64 |
BD | 64 |
Fällen | 64 |
Sie | 64 |
C1 | 64 |
calcineurin | 64 |
dann | 64 |
dar | 64 |
e. | 64 |
PGF | 63 |
August | 63 |
CTLA4 | 63 |
Fas | 63 |
HCC | 63 |
IG | 63 |
Nocardia | 63 |
Plerixafor | 63 |
Phase | 63 |
RA | 63 |
da | 63 |
immer | 63 |
p=0.01 | 63 |
SRL | 63 |
Immunsuppression | 62 |
Amphotericin | 62 |
CD16 | 62 |
EF1α | 62 |
GN | 62 |
HHV-7 | 62 |
ID | 62 |
Neutrophil | 62 |
NS | 62 |
Tagen | 62 |
bronchoalveolar | 62 |
liegt | 62 |
puede | 62 |
receptores | 62 |
Prevention | 62 |
Maßnahmen | 61 |
DOI | 61 |
Gruppe | 61 |
MLR | 61 |
Abb | 61 |
PD-1 | 61 |
Working | 61 |
ciency | 61 |
muss | 61 |
Spain | 61 |
busulfan | 60 |
CFU | 60 |
KG | 60 |
System | 60 |
Tac | 60 |
ca | 60 |
hiv | 60 |
obliterans | 60 |
β | 60 |
Treosulfan | 59 |
CAP | 59 |
Haploidentical | 59 |
Mann | 59 |
South | 59 |
TAC | 59 |
Chronic | 59 |
Trial | 59 |
pulmón | 59 |
trimethoprim | 59 |
bp | 59 |
Mensch | 59 |
i. | 59 |
cidofovir | 59 |
μg | 58 |
HO-1 | 58 |
rst | 58 |
BAFF | 58 |
BCV | 58 |
EC | 58 |
CA | 58 |
PTCy | 58 |
ROS | 58 |
Sirolimus | 58 |
Whitney | 58 |
insbesondere | 58 |
PI | 57 |
Alemtuzumab | 57 |
HDM | 57 |
IC | 57 |
Lung | 57 |
NR | 57 |
letermovir | 57 |
PIDD | 57 |
Thiotepa | 57 |
UC | 57 |
vasculopathy | 57 |
treten | 57 |
NBS | 56 |
CRP | 56 |
FA | 56 |
Leukemia | 56 |
Mel | 56 |
Rolle | 56 |
riesgo | 56 |
akuten | 56 |
haben | 56 |
infectie | 55 |
Ab | 55 |
DPB1 | 55 |
DRB1 | 55 |
GFP | 55 |
HAPLO | 55 |
IDO | 55 |
IFD | 55 |
Immunität | 55 |
Kaposi | 55 |
MD | 55 |
Substanzen | 55 |
TMP | 55 |
TT | 55 |
Verfügung | 55 |
Zur | 55 |
erfolgt | 55 |
immunodefi | 55 |
PICU | 55 |
Für | 54 |
London | 54 |
Korea | 54 |
FasL | 54 |
ECMO | 54 |
CTLA-4 | 54 |
V. | 54 |
PBSCT | 54 |
OVA | 54 |
andere | 54 |
etwa | 54 |
kB | 54 |
kan | 54 |
pg | 54 |
® | 54 |
μL | 54 |
enteropathy | 54 |
School | 53 |
Auch | 53 |
Donor | 53 |
IL-7 | 53 |
LRTI | 53 |
Non | 53 |
Primary | 53 |
Th17 | 53 |
W. | 53 |
ab | 53 |
bortezomib | 53 |
diese | 53 |
fludarabine | 53 |
innerhalb | 53 |
JC | 52 |
Chlamydia | 52 |
Emerson | 52 |
Enzephalitis | 52 |
IFA | 52 |
Inzidenz | 52 |
Abs | 52 |
PLT | 52 |
TRAIL | 52 |
VEGF | 52 |
alloreactive | 52 |
jiroveci | 52 |
lassen | 52 |
TM | 52 |
bronchiolitis | 51 |
FL | 51 |
Lymphoma | 51 |
New | 51 |
Organ | 51 |
Personen | 51 |
STAT3 | 51 |
ersten | 51 |
incidencia | 51 |
pp65 | 51 |
sollten | 51 |
trasplantados | 51 |
zoster | 51 |
RAG1 | 50 |
Acute | 50 |
Bedeutung | 50 |
CARD11 | 50 |
CC | 50 |
CID | 50 |
HEV | 50 |
PP | 50 |
Pediatrics | 50 |
während | 50 |
ROC | 50 |
SC | 50 |
SV40 | 50 |
aGvHD | 50 |
müssen | 50 |
p<0.0001 | 50 |
siRNA | 50 |
thiotepa | 50 |
CliniMACS | 49 |
ER | 49 |
FLT3-ITD | 49 |
Crohn | 49 |
Bcl-2 | 49 |
Asia | 49 |
IRIS | 49 |
France | 49 |
Haut | 49 |
PHA | 49 |
Ruxolitinib | 49 |
allografts | 49 |
effi | 49 |
op | 49 |
p<0.01 | 49 |
posaconazole | 49 |
postrasplante | 49 |
HDC | 48 |
Keine | 48 |
IST | 48 |
IS | 48 |
IL-23 | 48 |
C3 | 48 |
Fresenius | 48 |
Ergebnisse | 48 |
EASIX | 48 |
Monate | 48 |
Molecular | 48 |
NOD2 | 48 |
stellt | 48 |
Pharmaceuticals | 48 |
SP | 48 |
dL | 48 |
daher | 48 |
les | 48 |
mehr | 48 |
p= | 48 |
PML | 48 |
tritt | 48 |
veno | 48 |
February | 47 |
ITP | 47 |
IL-21 | 47 |
Listeria | 47 |
CpG | 47 |
A3 | 47 |
Kombination | 47 |
MCL | 47 |
Philadelphia | 47 |
WES | 47 |
chez | 47 |
finden | 47 |
hypogammaglobulinemia | 47 |
myelofibrosis | 47 |
Management | 47 |
Karnofsky | 46 |
PJ | 46 |
-2 | 46 |
CCR7 | 46 |
CD20 | 46 |
CTLs | 46 |
Ciclosporin | 46 |
GF | 46 |
Grade | 46 |
CP | 46 |
Ph | 46 |
beobachtet | 46 |
denen | 46 |
door | 46 |
infecciones | 46 |
n=5 | 46 |
prednisone | 46 |
ser | 46 |
stehen | 46 |
TC | 46 |
GVL | 45 |
LDH | 45 |
Kontakt | 45 |
IGRT | 45 |
CD86 | 45 |
FLT3 | 45 |
Daten | 45 |
DGF | 45 |
CF | 45 |
LLC | 45 |
Malaria | 45 |
Neben | 45 |
Y. | 45 |
übertragen | 45 |
haploHSCT | 45 |
bereits | 45 |
OKT3 | 45 |
X | 45 |
SMX | 45 |
PK | 45 |
Al | 44 |
Program | 44 |
Centre | 44 |
Control | 44 |
DN | 44 |
Fälle | 44 |
GBS | 44 |
Infections | 44 |
Myeloablative | 44 |
NTM | 44 |
Nicht | 44 |
CVC | 44 |
North | 44 |
SPSS | 44 |
lo | 44 |
Sect | 44 |
wordt | 44 |
qPCR | 44 |
n=6 | 44 |
mer | 44 |
▬ | 44 |
injerto | 44 |
frente | 44 |
alemtuzumab | 44 |
VGPR | 44 |
infl | 44 |
Cryptococcus | 43 |
HIES | 43 |
HHV-8 | 43 |
HCMV | 43 |
Cyclosporine | 43 |
CDI | 43 |
Clinic | 43 |
CFSE | 43 |
Antigen | 43 |
Liquor | 43 |
Aciclovir | 43 |
Laboratory | 43 |
Antibiotika | 43 |
MMR | 43 |
aufgrund | 43 |
MVA | 43 |
wurden | 43 |
nan | 43 |
infizierten | 43 |
beträgt | 43 |
globulin | 43 |
SVM | 43 |
Prophylaxis | 43 |
Nebenwirkungen | 43 |
NGS | 43 |
Monaten | 43 |
FLAMSA | 42 |
NT | 42 |
MV | 42 |
Los | 42 |
IM | 42 |
GC | 42 |
Prävention | 42 |
Durch | 42 |
DSS | 42 |
CD27 | 42 |
Antikörpern | 42 |
AIC | 42 |
Penicillin | 42 |
vom | 42 |
SCIG | 42 |
nachgewiesen | 42 |
tot | 42 |
su | 42 |
rechazo | 42 |
p=0.02 | 42 |
Syndrom | 42 |
han | 42 |
deren | 42 |
Treo | 42 |
TK | 42 |
ebenfalls | 42 |
Host | 41 |
LTR | 41 |
Infektionskrankheiten | 41 |
IfSG | 41 |
IO | 41 |
IL-13 | 41 |
Erwachsenen | 41 |
GCSF | 41 |
CIBMTR | 41 |
Bild | 41 |
Berlin | 41 |
Party | 41 |
MI | 41 |
Protein | 41 |
ook | 41 |
antigenemia | 41 |
ΔTK | 41 |
SNP | 41 |
m² | 41 |
konnte | 41 |
erfolgen | 41 |
allen | 41 |
XLA | 41 |
Studien | 41 |
Section | 41 |
SZT | 41 |
HS | 40 |
MinMax | 40 |
Miltenyi | 40 |
JE | 40 |
IL-1b | 40 |
PRA | 40 |
Ebola | 40 |
BSI | 40 |
AFP | 40 |
ABL | 40 |
NIAID | 40 |
ADV | 40 |
PS | 40 |
casos | 40 |
zijn | 40 |
weltweit | 40 |
n=12 | 40 |
metapneumovirus | 40 |
p=0.001 | 40 |
ZNS | 40 |
WB | 40 |
Survival | 40 |
Serum | 40 |
Parainfluenza | 40 |
CD1d | 39 |
FLAG | 39 |
Evaluation | 39 |
ELPT | 39 |
ED | 39 |
College | 39 |
ALPS | 39 |
Association | 39 |
Aldrich | 39 |
ATP | 39 |
ASC | 39 |
L1 | 39 |
+100 | 39 |
GBV | 39 |
Allergy | 39 |
Lee | 39 |
Prognose | 39 |
MK2 | 39 |
pancytopenia | 39 |
orale | 39 |
Symptomatik | 39 |
Rahmen | 39 |
steht | 39 |
Pneumokokken | 39 |
PJP | 39 |
Network | 39 |
NOD | 39 |
NMA | 39 |
Parvovirus | 39 |
Fisher | 38 |
Jazz | 38 |
Jahr | 38 |
Immunosuppression | 38 |
Foundation | 38 |
Division | 38 |
FSME | 38 |
Einsatz | 38 |
CE | 38 |
AST | 38 |
ALL | 38 |
Mycophenolate | 38 |
Letermovir | 38 |
Veränderungen | 38 |
Mycoplasma | 38 |
Po | 38 |
SI | 38 |
Scientific | 38 |
UL97 | 38 |
Z | 38 |
Zell | 38 |
Zu | 38 |
disease | 38 |
heute | 38 |
s. | 38 |
verschiedene | 38 |
weitere | 38 |
HMA | 37 |
FC | 37 |
FVIII | 37 |
DsRed | 37 |
Heart | 37 |
Leber | 37 |
Efficacy | 37 |
MFI | 37 |
CS | 37 |
CAV | 37 |
Balb | 37 |
BP | 37 |
ALC | 37 |
A20 | 37 |
Lymphozyten | 37 |
Abstoßung | 37 |
NAT | 37 |
ed | 37 |
SE | 37 |
ned | 37 |
voriconazole | 37 |
n= | 37 |
findet | 37 |
erforderlich | 37 |
spezifische | 37 |
deze | 37 |
Ursache | 37 |
Stuhl | 37 |
Spectra | 37 |
Seattle | 37 |
Sciences | 37 |
deutlich | 37 |
Campath | 36 |
NP | 36 |
MF | 36 |
LD | 36 |
EGFP | 36 |
DHR | 36 |
Centers | 36 |
Ara | 36 |
C2 | 36 |
BC | 36 |
Analysis | 36 |
Adam | 36 |
AZA | 36 |
Ramsauer | 36 |
Pilzinfektionen | 36 |
ORR | 36 |
Renal | 36 |
cytarabine | 36 |
Streptococcus | 36 |
≤ | 36 |
weniger | 36 |
uconazole | 36 |
spezifischen | 36 |
je | 36 |
g. | 36 |
p=0.002 | 36 |
auftreten | 36 |
Zahl | 36 |
World | 36 |
Wang | 36 |
Thymoglobulin | 36 |
Streptokokken | 36 |
ISS | 35 |
PRES | 35 |
Po0.001 | 35 |
P1 | 35 |
Novartis | 35 |
MST | 35 |
Legionella | 35 |
Klebsiella | 35 |
Impact | 35 |
ACR | 35 |
IPS | 35 |
ICOS | 35 |
FOXP3 | 35 |
CCR5 | 35 |
Burkholderia | 35 |
BTK | 35 |
AG | 35 |
-5 | 35 |
RZF | 35 |
QOL | 35 |
Rapamycin | 35 |
schwer | 35 |
diagnóstico | 35 |
zunächst | 35 |
wegen | 35 |
p=0.04 | 35 |
mayor | 35 |
lässt | 35 |
ggf | 35 |
gegenüber | 35 |
foscarnet | 35 |
TAM | 35 |
besonders | 35 |
WHO | 35 |
Use | 35 |
Typ | 35 |
Therapeutics | 35 |
TST | 35 |
TG | 35 |
WT1 | 35 |
HAV | 34 |
Lck | 34 |
LCMV | 34 |
Impfungen | 34 |
IL-1 | 34 |
HSP70 | 34 |
HBsAg | 34 |
CD80 | 34 |
Dr. | 34 |
Da | 34 |
CoV | 34 |
BW | 34 |
+3 | 34 |
Liver | 34 |
Nipah | 34 |
Verfahren | 34 |
Report | 34 |
entre | 34 |
sog | 34 |
polyomavirus | 34 |
min | 34 |
Ribavirin | 34 |
frecuente | 34 |
gr | 34 |
damit | 34 |
cepacia | 34 |
Voriconazole | 34 |
Varicella | 34 |
UA | 34 |
Chemotherapie | 33 |
HIVAN | 33 |
H5N1 | 33 |
GB | 33 |
Foxp3 | 33 |
Figure | 33 |
Defibrotide | 33 |
Day | 33 |
MPO | 33 |
Canada | 33 |
CD52 | 33 |
BoHV-4-A | 33 |
Bereich | 33 |
BRCA | 33 |
B6RgD | 33 |
Amgen | 33 |
ALT | 33 |
IGIV | 33 |
Acyclovir | 33 |
Organization | 33 |
beschrieben | 33 |
PBS | 33 |
te | 33 |
meisten | 33 |
mehrere | 33 |
kunnen | 33 |
hohe | 33 |
herpesvirus-6 | 33 |
se | 33 |
Zeichen | 33 |
Trimethoprim | 33 |
TCL | 33 |
Sanger | 33 |
San | 33 |
Pathology | 33 |
PMA | 33 |
Wahl | 33 |
HFOV | 32 |
Krankheitsbild | 32 |
Kingdom | 32 |
Index | 32 |
Immunantwort | 32 |
HSOS | 32 |
HGV | 32 |
COVID-19 | 32 |
HEPA | 32 |
EORTC | 32 |
DOCK8 | 32 |
BMF | 32 |
A6 | 32 |
A29LgD | 32 |
PPD | 32 |
PA | 32 |
KS | 32 |
Post | 32 |
maar | 32 |
Salmonella | 32 |
waren | 32 |
p=0.003 | 32 |
neg | 32 |
n=11 | 32 |
multiorgan | 32 |
mers | 32 |
niet | 32 |
hier | 32 |
Untersuchung | 32 |
W | 32 |
Valganciclovir | 32 |
VAD | 32 |
hasta | 32 |
En | 31 |
Epidemiologie | 31 |
Gene | 31 |
HA | 31 |
IE | 31 |
IP-10 | 31 |
Letalität | 31 |
Impfstoff | 31 |
Infection | 31 |
Les | 31 |
DP | 31 |
Drug | 31 |
AT | 31 |
DCD | 31 |
Consensus | 31 |
CTLA4Ig | 31 |
CD11c | 31 |
BIE | 31 |
AlloSCT | 31 |
ARF | 31 |
AP | 31 |
A1 | 31 |
-/- | 31 |
+180 | 31 |
Lyme | 31 |
Luminex | 31 |
IL | 31 |
MBL | 31 |
group | 31 |
MDSC | 31 |
wobei | 31 |
son | 31 |
pueden | 31 |
pos | 31 |
nivolumab | 31 |
letzten | 31 |
inmunosupresión | 31 |
immunsupprimierten | 31 |
herpesviruses | 31 |
handelt | 31 |
sowohl | 31 |
gestellt | 31 |
Methotrexate | 31 |
Zusammenhang | 31 |
MPN | 31 |
Meldepflicht | 31 |
Meningitis | 31 |
MPXV | 31 |
NPM1 | 31 |
Na | 31 |
RCC | 31 |
VRE | 31 |
Viral | 31 |
Microbiology | 30 |
HID | 30 |
Martin | 30 |
MAPK | 30 |
Klinik | 30 |
Intravenous | 30 |
Institutes | 30 |
Imatinib | 30 |
Häufigkeit | 30 |
Hizentra | 30 |
Care | 30 |
GalT | 30 |
GCV | 30 |
FLU | 30 |
FEV1 | 30 |
ERT | 30 |
CH50 | 30 |
Baltimore | 30 |
Anwendung | 30 |
Antigene | 30 |
AEs | 30 |
Neugeborenen | 30 |
Mittel | 30 |
Surgery | 30 |
Red | 30 |
i | 30 |
zeigen | 30 |
Robert | 30 |
voor | 30 |
verschiedenen | 30 |
später | 30 |
n=14 | 30 |
mo | 30 |
mito | 30 |
microangiopathy | 30 |
wieder | 30 |
häufigsten | 30 |
UNOS | 30 |
herpesvirus | 30 |
Switzerland | 30 |
Tapasin | 30 |
SIB | 30 |
Varizellen | 30 |
chronische | 30 |
conditioning | 30 |
galactomannan | 30 |
Data | 29 |
JNK | 29 |
JMML | 29 |
Herpesviren | 29 |
HSV-2 | 29 |
H-2 | 29 |
Entwicklung | 29 |
ESRD | 29 |
Development | 29 |
CD154 | 29 |
Chi | 29 |
CD5 | 29 |
CD31 | 29 |
CD18 | 29 |
CCR4 | 29 |
BEAC | 29 |
ALWP | 29 |
Las | 29 |
Krankheit | 29 |
VA | 29 |
MCP-1 | 29 |
mTOR | 29 |
Myc | 29 |
y.o | 29 |
vooral | 29 |
splenocytes | 29 |
p=0.03 | 29 |
p=0.004 | 29 |
max | 29 |
tocilizumab | 29 |
Von | 29 |
UTI | 29 |
Test | 29 |
SNPs | 29 |
Reaktivierung | 29 |
Objectives | 29 |
Netherlands | 29 |
zwei | 29 |
IL-5 | 28 |
HRQoL | 28 |
Hb | 28 |
Heidelberg | 28 |
Husten | 28 |
Kidney | 28 |
Immunisierung | 28 |
Indikation | 28 |
JCV | 28 |
Kindesalter | 28 |
Graft | 28 |
Gram | 28 |
Cbl | 28 |
GMP | 28 |
Form | 28 |
Fluconazol | 28 |
FDG | 28 |
ESHAP | 28 |
EM | 28 |
ELN | 28 |
Community | 28 |
M1RgD | 28 |
CG | 28 |
Allograft | 28 |
AHCT | 28 |
Li | 28 |
IPEX | 28 |
MLC | 28 |
einigen | 28 |
Masern | 28 |
ϭ | 28 |
viremia | 28 |
reg | 28 |
möglichst | 28 |
meta | 28 |
invasora | 28 |
hoher | 28 |
hepatosplenomegaly | 28 |
haploinsufficiency | 28 |
gehören | 28 |
erst | 28 |
hyperimmune | 28 |
bezeichnet | 28 |
Tat | 28 |
RTBV | 28 |
basiliximab | 28 |
Rag1 | 28 |
ST2 | 28 |
Systems | 28 |
TLR2 | 28 |
U. | 28 |
Untersuchungen | 28 |
Wirksamkeit | 28 |
aller | 28 |
JAK2 | 27 |
Le | 27 |
Institution | 27 |
Jaccard | 27 |
Jurkat | 27 |
LFA-1 | 27 |
LV | 27 |
MFD | 27 |
Leishmania | 27 |
M1 | 27 |
M2 | 27 |
MDR | 27 |
Measles | 27 |
Mortalität | 27 |
IL2RG | 27 |
Institut | 27 |
Adv | 27 |
Gegensatz | 27 |
Foscarnet | 27 |
Folge | 27 |
FBS | 27 |
Escherichia | 27 |
Erregern | 27 |
Enterobacteriaceae | 27 |
CXR | 27 |
CHH | 27 |
CDV | 27 |
BuCy | 27 |
BSA | 27 |
AIRE | 27 |
AIHA | 27 |
NSG | 27 |
NB | 27 |
dat | 27 |
Organe | 27 |
anderer | 27 |
virale | 27 |
stellen | 27 |
PMN | 27 |
n=4 | 27 |
n=13 | 27 |
leu | 27 |
hohen | 27 |
fluconazole | 27 |
est | 27 |
entwickeln | 27 |
donante | 27 |
autoSCT | 27 |
autoHSCT | 27 |
antigen | 27 |
pH | 27 |
aantal | 27 |
SS | 27 |
aan | 27 |
PTX3 | 27 |
Polyomavirus | 27 |
Q | 27 |
RAPA | 27 |
Republic | 27 |
Pneumonien | 27 |
STR | 27 |
VTD | 27 |
Stämme | 27 |
Tag | 27 |
Sepsis | 27 |
Zoster | 27 |
LMP1 | 26 |
LOS | 26 |
LSEC | 26 |
MCP | 26 |
MOI | 26 |
nan | 26 |
Michael | 26 |
PIV | 26 |
Review | 26 |
Risk | 26 |
IDSA | 26 |
Roche | 26 |
IPSS | 26 |
Cephalosporine | 26 |
HSCT2 | 26 |
GVT | 26 |
Familie | 26 |
Erregernachweis | 26 |
Detection | 26 |
DIPSS | 26 |
DF | 26 |
CRV | 26 |
CPE | 26 |
Alle | 26 |
Akt | 26 |
AI | 26 |
Schwangeren | 26 |
SF | 26 |
seltener | 26 |
Schwangerschaft | 26 |
cytopenia | 26 |
Symptomen | 26 |
zeigt | 26 |
weisen | 26 |
viralen | 26 |
sondern | 26 |
sida | 26 |
pentamidine | 26 |
micafungin | 26 |
histolytica | 26 |
gB | 26 |
efectos | 26 |
diesen | 26 |
n=15 | 26 |
cytometric | 26 |
Verdacht | 26 |
biopsy | 26 |
TX | 26 |
Th2 | 26 |
Therapy | 26 |
Urin | 26 |
TNFa | 26 |
Vero | 26 |
Virology | 26 |
Wiskott | 26 |
antilymphocyte | 26 |
IL-12p40 | 25 |
H2AX | 25 |
HA-1 | 25 |
Herpesvirus | 25 |
Huang | 25 |
IFNg | 25 |
Inc. | 25 |
IRB | 25 |
Fluconazole | 25 |
Klinische | 25 |
NC | 25 |
NFAT | 25 |
PE | 25 |
GOF | 25 |
Además | 25 |
FluMel | 25 |
Endokarditis | 25 |
Class | 25 |
Central | 25 |
CMVIG | 25 |
CD45RA | 25 |
CD107a | 25 |
CARV | 25 |
Beginn | 25 |
Banff | 25 |
B6 | 25 |
Advisory | 25 |
PRCA | 25 |
Academy | 25 |
PLC | 25 |
Newcastle | 25 |
Practice | 25 |
einige | 25 |
Primärinfektion | 25 |
wichtigsten | 25 |
weiteren | 25 |
viruria | 25 |
viral | 25 |
syndrome | 25 |
spielen | 25 |
schon | 25 |
neben | 25 |
mindestens | 25 |
meses | 25 |
mL. | 25 |
infi | 25 |
ou | 25 |
desarrollo | 25 |
Thomas | 25 |
RIT | 25 |
caspofungin | 25 |
Reaktionen | 25 |
Risikofaktoren | 25 |
Schutz | 25 |
Säuglingen | 25 |
Spezies | 25 |
a. | 25 |
allerdings | 25 |
ammatory | 25 |
azithromycin | 25 |
busulphan | 25 |
Interferon | 24 |
GPU | 24 |
GTKO | 24 |
Guidelines | 24 |
HHV | 24 |
IL-33 | 24 |
Impfstoffe | 24 |
Med | 24 |
John | 24 |
Lassa | 24 |
Liu | 24 |
Log | 24 |
MR | 24 |
Exanthem | 24 |
GH | 24 |
A7 | 24 |
Eq | 24 |
Nef | 24 |
Enterococcus | 24 |
Empfänger | 24 |
Ektoparasiten | 24 |
EDSS | 24 |
Ca | 24 |
CPAP | 24 |
CD44 | 24 |
Beteiligung | 24 |
Assessment | 24 |
Aedes | 24 |
Administration | 24 |
A8 | 24 |
A10 | 24 |
NCF1 | 24 |
Vergleich | 24 |
PG | 24 |
USIDNET | 24 |
Pilze | 24 |
órgano | 24 |
zugelassen | 24 |
valacyclovir | 24 |
typischen | 24 |
sobre | 24 |
seit | 24 |
non | 24 |
ne | 24 |
hoch | 24 |
haploidentical | 24 |
du | 24 |
chronischen | 24 |
bestimmten | 24 |
obliterante | 24 |
Toxoplasma | 24 |
Schmerzen | 24 |
Toll | 24 |
Pradesh | 24 |
S1 | 24 |
SA | 24 |
SB | 24 |
Schlussfolgerungen | 24 |
Scedosporium | 24 |
Science | 24 |
Strongyloides | 24 |
TPH | 24 |
Taiwan | 24 |
Tc | 24 |
Tg | 24 |
CyBor | 23 |
Erregers | 23 |
Dec | 23 |
Di | 23 |
EMT | 23 |
EP | 23 |
EPAG | 23 |
East | 23 |
HP | 23 |
Europa | 23 |
FMDV | 23 |
Fanconi | 23 |
Frauen | 23 |
Geburt | 23 |
General | 23 |
HEK293 | 23 |
Chagas | 23 |
Chen | 23 |
AKI | 23 |
CVD | 23 |
Basel | 23 |
-4 | 23 |
/d | 23 |
IHC | 23 |
Arten | 23 |
Aufgrund | 23 |
Austria | 23 |
BTV | 23 |
Beim | 23 |
CTV | 23 |
Bestimmung | 23 |
Biology | 23 |
Brincidofovir | 23 |
CARD15 | 23 |
CD45RA+ | 23 |
CD69 | 23 |
CRE | 23 |
Helicobacter | 23 |
G1 | 23 |
IPI | 23 |
U.S. | 23 |
Virusvermehrung | 23 |
Vor | 23 |
Wilcoxon | 23 |
Zeitpunkt | 23 |
Zhang | 23 |
akute | 23 |
cm | 23 |
idelalisib | 23 |
infecties | 23 |
itraconazole | 23 |
iv | 23 |
miRNAs | 23 |
muy | 23 |
rituximab | 23 |
tras | 23 |
une | 23 |
Kopfschmerzen | 23 |
Universitario | 23 |
gute | 23 |
Tol | 23 |
Singapore | 23 |
LP | 23 |
Teil | 23 |
Lymphknoten | 23 |
MO | 23 |
Mit | 23 |
Neisseria | 23 |
SCN | 23 |
NE | 23 |
Speichel | 23 |
Spektrum | 23 |
Stunden | 23 |
TEC | 23 |
TI | 23 |
TLRs | 23 |
TTV | 23 |
High | 22 |
Infizierten | 22 |
Infektionskrankheit | 22 |
IFN- | 22 |
HaploSCT | 22 |
Herpesviridae | 22 |
HSCs | 22 |
Hantavirus | 22 |
Konjunktivitis | 22 |
Israel | 22 |
OX40 | 22 |
LRBA | 22 |
Lunge | 22 |
MAI | 22 |
MICA | 22 |
NIV | 22 |
Nierentransplantation | 22 |
Optia | 22 |
PAI-1 | 22 |
HDL | 22 |
HI | 22 |
Alter | 22 |
H&E | 22 |
German | 22 |
PSC | 22 |
A5 | 22 |
AlloHSCT | 22 |
Aus | 22 |
Auto | 22 |
Barcelona | 22 |
Bartonella | 22 |
Bcl | 22 |
Blumberg | 22 |
Bortezomib | 22 |
Brazil | 22 |
Bronchiolitis | 22 |
DCM | 22 |
DE | 22 |
Dengue | 22 |
Dosierung | 22 |
FCXM | 22 |
Free | 22 |
G2 | 22 |
PNP | 22 |
haploSCT | 22 |
Professor | 22 |
n=1 | 22 |
etanercept | 22 |
evtl | 22 |
factores | 22 |
gancyclovir | 22 |
hepatomegaly | 22 |
lang | 22 |
liegen | 22 |
miRNA | 22 |
n=22 | 22 |
empleo | 22 |
neumonitis | 22 |
o. | 22 |
p=0.005 | 22 |
prevención | 22 |
thymoglobulin | 22 |
verbreitet | 22 |
virus | 22 |
QoL | 22 |
este | 22 |
n=17 | 22 |
eher | 22 |
Transmission | 22 |
RDW | 22 |
cytopenias | 22 |
Reduktion | 22 |
Resistenz | 22 |
SIR | 22 |
Service | 22 |
Standard | 22 |
TLI | 22 |
TaqMan | 22 |
wirksam | 22 |
VHH-6 | 22 |
Virämie | 22 |
aa | 22 |
abatacept | 22 |
aciclovir | 22 |
bestehen | 22 |
Univariate | 22 |
choriomeningitis | 22 |
chorioretinitis | 22 |
First | 21 |
Grundlagen | 21 |
HpSC | 21 |
Hg | 21 |
HHVs | 21 |
GPI | 21 |
Green | 21 |
GVH | 21 |
Immunol | 21 |
GITMO | 21 |
Flow | 21 |
IL2 | 21 |
Median | 21 |
Integrated | 21 |
LCL | 21 |
MLL | 21 |
MPS | 21 |
Medikamente | 21 |
Methodik | 21 |
Mofetil | 21 |
Monoclonal | 21 |
Natural | 21 |
Novel | 21 |
PBPC | 21 |
NOS | 21 |
Board | 21 |
Faculty | 21 |
Evans | 21 |
Plasma | 21 |
ABA | 21 |
AGVHD | 21 |
Befunde | 21 |
Bio | 21 |
Boston | 21 |
CD10 | 21 |
CD152 | 21 |
CM | 21 |
CO | 21 |
CV | 21 |
California | 21 |
Coronavirus | 21 |
DIC | 21 |
Darm | 21 |
Dauer | 21 |
Deficiency | 21 |
Dosis | 21 |
E2 | 21 |
Entamoeba | 21 |
Enteroviren | 21 |
Epidemiology | 21 |
Erbrechen | 21 |
PIRCHE | 21 |
Everolimus | 21 |
Prodigy | 21 |
infektiösen | 21 |
azole | 21 |
año | 21 |
d0 | 21 |
drei | 21 |
durante | 21 |
entwickelt | 21 |
erhalten | 21 |
gelegentlich | 21 |
gondii | 21 |
hPL | 21 |
hin | 21 |
invasiven | 21 |
atovaquone | 21 |
leicht | 21 |
multicentre | 21 |
möglicherweise | 21 |
paciente | 21 |
plasmacytoid | 21 |
presentan | 21 |
primeros | 21 |
rasch | 21 |
wahrscheinlich | 21 |
≥ | 21 |
Rux | 21 |
au | 21 |
sinnvoll | 21 |
aspergillosis | 21 |
Th | 21 |
antistoffen | 21 |
SIGN1AT1 | 21 |
Schwere | 21 |
Sensitivität | 21 |
Sigma | 21 |
Stadium | 21 |
Staphylokokken | 21 |
Studie | 21 |
TLR7 | 21 |
TREO | 21 |
TSV | 21 |
STIKO | 21 |
Thymoglobuline | 21 |
Unter | 21 |
VA1 | 21 |
VEB | 21 |
Veno | 21 |
Viele | 21 |
Vordergrund | 21 |
Wegen | 21 |
Yu | 21 |
Woche | 21 |
Total | 21 |
GL | 20 |
Haematology | 20 |
Gradients | 20 |
Giardia | 20 |
FCS | 20 |
Fischer | 20 |
FMD | 20 |
FE | 20 |
Etoposide | 20 |
Het | 20 |
LIC | 20 |
Hierbei | 20 |
IGSC | 20 |
ITD | 20 |
Jan | 20 |
LTX | 20 |
Labor | 20 |
Lebensjahr | 20 |
MCs | 20 |
MPA | 20 |
Delhi | 20 |
Makrophagen | 20 |
Einfluss | 20 |
CDR3 | 20 |
David | 20 |
Biotec | 20 |
Methods | 20 |
-1 | 20 |
A9 | 20 |
ADCC | 20 |
ALF | 20 |
Andere | 20 |
Ankara | 20 |
BHK | 20 |
Bevölkerung | 20 |
Bioverfügbarkeit | 20 |
DM | 20 |
CEBPA | 20 |
CMV-3A | 20 |
CTA | 20 |
Childrens | 20 |
Co | 20 |
Conference | 20 |
Congo | 20 |
Cyclosporin | 20 |
DD | 20 |
Maria | 20 |
Mutter | 20 |
häufiger | 20 |
methylprednisolone | 20 |
begomovirus | 20 |
bisher | 20 |
cyclosporine | 20 |
derzeit | 20 |
después | 20 |
estudios | 20 |
gamma | 20 |
grupo | 20 |
kein | 20 |
n=16 | 20 |
association | 20 |
oft | 20 |
scheint | 20 |
selectin | 20 |
sont | 20 |
systemischen | 20 |
tipo | 20 |
vedotin | 20 |
NLR | 20 |
welche | 20 |
aunque | 20 |
dan | 20 |
Zeit | 20 |
Sanofi | 20 |
O. | 20 |
PICC | 20 |
POS | 20 |
Pathogenese | 20 |
Paya | 20 |
Posttransplant | 20 |
Wirkung | 20 |
RTC | 20 |
RVI | 20 |
SH3 | 20 |
Proteine | 20 |
TD | 20 |
TTP | 20 |
Tcells | 20 |
Tieren | 20 |
Tonsillopharyngitis | 20 |
Turkey | 20 |
URTI | 20 |
VHC | 20 |
Vermeidung | 20 |
Fever | 19 |
Healthcare | 19 |
HUS | 19 |
HERV | 19 |
GG | 19 |
FU | 19 |
Fall | 19 |
Faktoren | 19 |
Einführung | 19 |
Empfehlungen | 19 |
Hendra | 19 |
Hemmung | 19 |
Lin | 19 |
Hinweise | 19 |
IB | 19 |
IgG1 | 19 |
Immunsystems | 19 |
Indikationen | 19 |
Innsbruck | 19 |
Jugendlichen | 19 |
Kap | 19 |
Killer | 19 |
LDLT | 19 |
E3 | 19 |
ECD | 19 |
-7 | 19 |
Dept | 19 |
Aufnahme | 19 |
+365 | 19 |
+60 | 19 |
2y | 19 |
ACT | 19 |
ASD | 19 |
Agenzien | 19 |
Alem | 19 |
Analyse | 19 |
Antibody | 19 |
Assay | 19 |
Azathioprin | 19 |
DICEP | 19 |
BCNU | 19 |
Beschwerden | 19 |
Bildung | 19 |
Blutkultur | 19 |
Brown | 19 |
CBU | 19 |
CD19-CAR | 19 |
CVE | 19 |
Celgene | 19 |
City | 19 |
Langerhans | 19 |
spricht | 19 |
MEL | 19 |
aHSCT | 19 |
aparición | 19 |
bronquiolitis | 19 |
cellen | 19 |
day | 19 |
denken | 19 |
esta | 19 |
hematoxylin | 19 |
ihre | 19 |
interstitielle | 19 |
kb | 19 |
krusei | 19 |
qRT | 19 |
receptor | 19 |
reduziert | 19 |
seronegativos | 19 |
spielt | 19 |
supervivencia | 19 |
tegen | 19 |
wichtige | 19 |
wirksame | 19 |
zellulären | 19 |
≥2 | 19 |
MEL200 | 19 |
antivirale | 19 |
p=0.05 | 19 |
YF | 19 |
TE | 19 |
MMP-9 | 19 |
Wirkspektrum | 19 |
Mycophenolat | 19 |
NADPH | 19 |
OA | 19 |
Peter | 19 |
SDS | 19 |
Serotypen | 19 |
Stammzelltransplantation | 19 |
T2 | 19 |
TCRαβ | 19 |
SUV | 19 |
TP53 | 19 |
TSLP | 19 |
Tconv | 19 |
Tuberculosis | 19 |
VD | 19 |
Vancomycin | 19 |
Vg9Vd2 | 19 |
TLR3 | 19 |
Virusinfektionen | 19 |
WJ | 19 |
Genetics | 18 |
Hier | 18 |
ISA | 18 |
IPA | 18 |
Hsp90 | 18 |
Honoraria | 18 |
HMGB1 | 18 |
Hib | 18 |
HPLC | 18 |
HPC | 18 |
HFRS | 18 |
Iran | 18 |
IgD | 18 |
Milan | 18 |
JAK | 18 |
Janssen | 18 |
KDR | 18 |
King | 18 |
Kombinationstherapie | 18 |
Kotton | 18 |
MDCK | 18 |
MP | 18 |
Maribavir | 18 |
Meningokokken | 18 |
Myeloma | 18 |
NTC8685 | 18 |
GD | 18 |
GTPV | 18 |
AIH | 18 |
GCT | 18 |
Freiburg | 18 |
PI3 | 18 |
30mg | 18 |
AAD | 18 |
ANOVA | 18 |
AU | 18 |
Ad | 18 |
Ann | 18 |
Australia | 18 |
Belgium | 18 |
Box | 18 |
CD33 | 18 |
CD38 | 18 |
CKD | 18 |
COPD | 18 |
Castleman | 18 |
Cells | 18 |
Chicago | 18 |
Conclusions | 18 |
Coro1a | 18 |
DLT | 18 |
Dexamethasone | 18 |
ERAAP | 18 |
Entstehung | 18 |
Expression | 18 |
FK | 18 |
Neugeborene | 18 |
Poland | 18 |
PMF | 18 |
kaum | 18 |
bilden | 18 |
células | 18 |
dans | 18 |
diesem | 18 |
diferentes | 18 |
diffi | 18 |
dosis | 18 |
hMSCs | 18 |
hervorgerufen | 18 |
hohem | 18 |
inotropic | 18 |
insgesamt | 18 |
menor | 18 |
aggrecan | 18 |
otros | 18 |
polyoma | 18 |
positiven | 18 |
resistente | 18 |
seltenen | 18 |
signifikant | 18 |
uL | 18 |
ug | 18 |
verursachen | 18 |
viele | 18 |
zoals | 18 |
Para | 18 |
benefi | 18 |
maltophilia | 18 |
Ziel | 18 |
SLPI | 18 |
Zagreb | 18 |
Paris | 18 |
Patients | 18 |
Pharma | 18 |
Pittsburgh | 18 |
Po0.05 | 18 |
À1 | 18 |
Prionen | 18 |
RTSV | 18 |
Rice | 18 |
SF-36 | 18 |
SGA | 18 |
Polymerase | 18 |
Thio | 18 |
Serologie | 18 |
T3 | 18 |
TACE | 18 |
TCRab | 18 |
TGFb1 | 18 |
TLR9 | 18 |
Transplantat | 18 |
Trypanosoma | 18 |
Type | 18 |
SPPV | 18 |
Wien | 18 |
HSV-1 | 17 |
HPIV | 17 |
HSCT1 | 17 |
Funding | 17 |
Grund | 17 |
HT | 17 |
H2 | 17 |
GR | 17 |
Great | 17 |
Glomerulonephritis | 17 |
Genzyme | 17 |
GenBank | 17 |
Gattung | 17 |
IBM | 17 |
Hannover | 17 |
NTC8485 | 17 |
ICAM-1 | 17 |
IgG. | 17 |
Immundefizienz | 17 |
Isakov | 17 |
KT | 17 |
Kontrolle | 17 |
Learning | 17 |
Louis | 17 |
MHCII | 17 |
MZ | 17 |
N=1 | 17 |
NCs | 17 |
Nature | 17 |
Exposition | 17 |
FCM | 17 |
Abhängigkeit | 17 |
Exome | 17 |
CCL2 | 17 |
AF | 17 |
AM | 17 |
Nov | 17 |
Adenoviral | 17 |
Adenoviren | 17 |
Afrika | 17 |
Andhra | 17 |
Anzahl | 17 |
Aspergillose | 17 |
Ausmaß | 17 |
Basiliximab | 17 |
Burkitt | 17 |
Busulphan | 17 |
CCR2 | 17 |
Entzündung | 17 |
CD1a | 17 |
CYBB | 17 |
Clin | 17 |
Clindamycin | 17 |
Cytarabine | 17 |
Danziger | 17 |
Deep | 17 |
DilC | 17 |
ECOG | 17 |
EV | 17 |
Eastern | 17 |
Eltrombopag | 17 |
Ende | 17 |
Niere | 17 |
KDIGO | 17 |
Organtransplantation | 17 |
lymphotropic | 17 |
asymptomatisch | 17 |
bakteriellen | 17 |
beide | 17 |
beiden | 17 |
cacy | 17 |
control | 17 |
dagegen | 17 |
einzelnen | 17 |
empfohlen | 17 |
glomerulopathy | 17 |
h. | 17 |
ibrutinib | 17 |
infektiöse | 17 |
lymphoproliferative | 17 |
mediastinitis | 17 |
ZdCyd | 17 |
metronidazole | 17 |
neue | 17 |
nonmalignant | 17 |
notwendig | 17 |
p=0 | 17 |
patiënten | 17 |
psittaci | 17 |
schwere | 17 |
tasas | 17 |
unterscheidet | 17 |
verabreicht | 17 |
verwendet | 17 |
zich | 17 |
Overall | 17 |
aspergilosis | 17 |
n=32 | 17 |
Wie | 17 |
SCM | 17 |
P2 | 17 |
Verläufe | 17 |
PBST | 17 |
Patel | 17 |
Pearson | 17 |
Pre | 17 |
Prism | 17 |
RAEB | 17 |
RICT | 17 |
Rac1 | 17 |
Replikation | 17 |
Roquin | 17 |
S2 | 17 |
RAG2 | 17 |
Se | 17 |
TAP1 | 17 |
Typen | 17 |
Spender | 17 |
Titer | 17 |
TPO | 17 |
TMI | 17 |
TCMR | 17 |
TDM | 17 |
Swiprosin-1 | 17 |
Sun | 17 |
State | 17 |
Springer | 17 |
Valacyclovir | 17 |
Kim | 16 |
Intensive | 16 |
LM | 16 |
KNN | 16 |
Italian | 16 |
Invitrogen | 16 |
LTV | 16 |
Intracellular | 16 |
Internal | 16 |
IND | 16 |
Instituto | 16 |
Illumina | 16 |
IgG4-RD | 16 |
IRF3 | 16 |
IL-2R | 16 |
Lymphocyte | 16 |
IDA | 16 |
Hyper | 16 |
Leiden | 16 |
PIDs | 16 |
MSI | 16 |
MYCN | 16 |
HRV | 16 |
Plasmodium | 16 |
Phl | 16 |
Panel | 16 |
PTDM | 16 |
PKR | 16 |
PCNSL | 16 |
PBL | 16 |
PBC | 16 |
PAN | 16 |
Ostmeyer | 16 |
Neutropenie | 16 |
Nagler | 16 |
NMD | 16 |
Munich | 16 |
Multiple | 16 |